Systemic lupus erythematosus

@article{Kaul2016SystemicLE,
  title={Systemic lupus erythematosus},
  author={Arvind Kaul and Caroline Gordon and Mary K Crow and Zahi Touma and Murray B. Urowitz and Ronald F. van Vollenhoven and Guillermo Ruiz-Irastorza and Graham R. V. Hughes},
  journal={Nature Reviews Disease Primers},
  year={2016},
  volume={2}
}
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect many organs, including the skin, joints, the central nervous system and the kidneys. Women of childbearing age and certain racial groups are typically predisposed to developing the condition. Rare, inherited, single-gene complement deficiencies are strongly associated with SLE, but the disease is inherited in a polygenic manner in most patients. Genetic interactions with environmental factors, particularly UV light… Expand

Paper Mentions

Interventional Clinical Trial
The first phase of this pilot study will assess changes in quality of life at the end of a 16-week Mymee program in patients with moderate to severe SLE. The second phase will assess… Expand
ConditionsSystem; Lupus Erythematosus
InterventionBehavioral
SYSTEMIC LUPUS ERYTHEMATOSUS - AN IMMUNOLOGICAL DISORDER: CLINICAL PRESENTATIONS AND THERAPEUTIC OPTIONS
TLDR
New treatment options for SLE include Belimumab, Mycophenolate mofetil, intravenous immunoglobulins, Rituximab, Atacicept etc. main purpose of addition of new treatment modalities is prevention of complications of conventional treatment and to look for better therapeutic options. Expand
Vitamin D and juvenile systemic lupus erythematosus: Lights, shadows and still unresolved issues.
TLDR
The innumerable correlations between vitamin D and disease activity, including clinical expression and gene polymorphisms of vitamin D receptor as well as the recommendations for vitamin D supplementation in patients with SLE and jSLE are discussed. Expand
P-Glycoprotein and Drug Resistance in Systemic Autoimmune Diseases
TLDR
Observations suggest that P-gp antagonists could be adopted to revert drug resistance and improve disease outcome. Expand
Problems of early diagnosis of systemic lupus erythematosus during the COVID-19 pandemic
TLDR
Difficulties in diagnosing SLE during the COVID-19 pandemic are considered, and particular attention is paid to the comparative characteristics of the immunopathological mechanisms of SLE and CO VID-19. Expand
Ocular Manifestations of Systemic Lupus Erythematosus
TLDR
Ocular involvement may precede systemic onset of the disease and early recognition of ocular disease by an ophthalmologist may prevent not only the blinding complications of SLE but also alert the clinician to the likely presence of disease activity elsewhere and timely institution of systemic therapy. Expand
Lupus nephritis
TLDR
This Primer reviews the epidemiology of lupus nephritis, its pathogenesis and advances in its treatment and concludes that early and accurate diagnosis of LN and prompt initiation of therapy are of vital importance to improve outcomes in patients with SLE. Expand
Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus (NPSLE): Can They Be Used as Biomarkers for the Differential Diagnosis of This Disease?
  • E. Manca
  • Medicine
  • Clinical Reviews in Allergy & Immunology
  • 2021
TLDR
In this review, the most relevant data is reported with regard to mechanisms implicated in the production of autoantibodies and the most important autoantsibodies found among patients with systemic lupus erythematosus with and without the neuropsychiatric manifestations. Expand
Can the SARS-CoV-2 infection trigger systemic lupus erythematosus? A case-based review
TLDR
Through a systematic search of the medical literature, two cases with newly onset SLE and five cases with previous SLE diagnosis that showed activity of the disease due to SARS-CoV-2 infection are retrieved and a systemic review is presented. Expand
Systemic Lupus Erythematous: Symptoms and Signs at Initial Presentations.
TLDR
This is the first study of the symptoms and signs at initial clinical presentation of SLE patients compared to other studies done regionally where most have focused on clinical manifestations during the progression course of Sle. Expand
Evolving story of autoantibodies in systemic lupus erythematosus.
TLDR
Clinically, ANA testing has new uses for determining classification as well as assessing eligibility for clinical trials and the importance of understanding autoantigenicity and developing sensitive and informative assays for clinical assessments is highlighted. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 400 REFERENCES
Pathogenesis of human systemic lupus erythematosus: recent advances.
TLDR
This work reviews recent findings that deal with genes associated with disease expression, immune cell molecular abnormalities that lead to autoimmune pathology, and the role of hormones and sex chromosomes in the development of disease. Expand
Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers
TLDR
The manifestation and pathogenesis of NPSLE is reviewed, focusing on the features that might aid identification of potential biomarkers, which are needed to improve prediction of disease outcomes and guide treatment. Expand
Molecular aberrations in human systemic lupus erythematosus.
TLDR
Enhanced understanding of molecular abnormalities in systemic lupus erythematosus reflect disordered biochemical and molecular functions that might be determined genetically, and should enable development of new, effective therapeutic agents in the near future. Expand
Systemic lupus erythematosus
TLDR
Systemic lupus erythematosus is a relapsing and remitting disease, and treatment aims are threefold: managing acute periods of potentially life-threatening ill health, minimizing the risk of flares during periods of relative stability, and controlling the less life- threatening, but often incapacitating day to day symptoms. Expand
Cytokines as therapeutic targets in SLE
TLDR
The rationale for anticytokine therapies in SLE is discussed and review agents currently in use, and those being developed and tested experimentally, as well as suggestions for the future of treatment for SLE, including new therapeutic strategies. Expand
Genetic susceptibility to systemic lupus erythematosus in the genomic era
TLDR
Genetic risk factors that are shared between SLE and other immune-related diseases highlight common pathways in the pathophysiology of these diseases, and might provide innovative molecular targets for therapeutic interventions. Expand
Recent insights into the genetic basis of systemic lupus erythematosus
TLDR
Many susceptibility genes fall into key pathways that are consistent with previous studies implicating immune complexes, host immune signal transduction and interferon pathways in the pathogenesis of SLE. Expand
Immunological and clinical differences between juvenile and adult onset of systemic lupus erythematosus
TLDR
Investigation of immunological and clinical characteristics of SLE juvenile onset and SLE adult onset suggests the most severe clinical manifestations in the juvenile-onset SLE group are not related with the presence of studied antibodies by different methods. Expand
The management of systemic lupus erythematosus: Facts and controversies.
TLDR
The current treatment for systemic lupus erythematosus, using anti-inflammatory, antimalarial, and immunosuppressive agents, is fairly effective, but serious adverse events are possible. Expand
Inflammatory etiopathogenesis of systemic lupus erythematosus: an update
TLDR
Current knowledge about the etiopathogenesis of SLE is reviewed including the involvement of different types of cell death, serving as the potential source of autoantigens, and impaired clearance of cell remnants, causing accumulation of cellular debris. Expand
...
1
2
3
4
5
...